Pulmonary Fibrosis and Oxygen Therapy

Pulmonary fibrosis progressively thickens and scars the interstitium, diminishing alveolar surface area and lengthening diffusion distance for oxygen. This pathophysiology manifests first as exertional hypoxemia because physical activity shortens capillary transit time and magnifies the diffusion barrier; over time, resting hypoxemia often develops. Supplemental oxygen directly addresses this gas‑exchange deficit by raising the fraction of inspired oxygen, increasing alveolar oxygen tension, and thus the gradient driving diffusion into blood. Clinically, oxygen reduces dyspnea and can improve exercise capacity, enabling patients to perform daily tasks and participate in pulmonary rehabilitation. Guidelines from major societies recommend long‑term oxygen for people with interstitial lung disease who have severe chronic resting hypoxemia, acknowledging that the certainty of evidence is lower than in COPD yet the physiologic rationale and patient‑centered benefits are compelling. Ambulatory oxygen is suggested for those with significant exertional desaturation, supported by randomized crossover data showing improvements in breathlessness and health‑related quality of life. Nocturnal oxygen is considered when sleep studies or overnight oximetry reveal desaturation, though robust outcome data remain limited. High‑flow nasal cannula, which delivers heated, humidified oxygen at higher flows to reduce room‑air entrainment and work of breathing, is used in hospitals and selectively at home; evidence in outpatient pulmonary fibrosis is still emerging. Practical implementation entails matching device type to lifestyle: stationary concentrators for home, portable concentrators or cylinders for community mobility, and—where available—liquid oxygen for high flows at lighter weight. Clinicians titrate flow to meet guideline saturation targets during rest, sleep, and exertion. Safety is paramount: oxygen supports combustion, so strict no‑smoking policies and fire precautions are essential. Nasal dryness, skin irritation, and tubing hazards are common but manageable; carbon dioxide retention is uncommon in isolated fibrosis but warrants vigilance if there is overlap with other conditions. Insurance and coverage vary by region and criteria, which can affect access to ambulatory systems. Integrating oxygen with antifibrotic therapy, pulmonary rehabilitation, vaccination, and comorbidity management offers the most comprehensive approach, while palliative care ensures that treatment intensity aligns with patient goals as disease advances.

Traditional frameworks approach breathlessness as a disturbance of vital energy and balance rather than a single structural defect. In Traditional Chinese Medicine, pulmonary fibrosis–related dyspnea may be conceptualized as Lung qi deficiency complicated by phlegm and blood stasis. Treatment emphasizes tonifying Lung and Spleen qi to support energy, resolving phlegm to ease chest fullness, and moving blood to reduce stagnation that can worsen fatigue and discomfort. Techniques include individualized herbal formulas, acupuncture to modulate respiratory effort and calm the shen (spirit), and qigong to coordinate breath and movement. In Ayurveda, breathlessness can reflect vata derangement and kapha accumulation; gentle pranayama, attention to digestion and nourishment, and restorative routines are used to maintain ojas (vitality) and reduce symptom burden. These traditions do not position their therapies as substitutes for oxygen when hypoxemia is present; rather, they provide supportive tools that may enhance comfort, reduce anxiety, and improve functional coping. Breathwork practices—qigong, tai chi, and pranayama—encourage slow, coordinated breathing, which can lower the perception of dyspnea, complement pacing strategies, and help patients synchronize with oxygen delivery during activity. Acupuncture has been used for breathlessness and stress, with small studies in chronic lung disease suggesting improvements in symptoms and quality of life. Nutrition and gentle strengthening support resilience, while mindful movement mitigates deconditioning. An integrative plan brings these elements together with biomedical care: oxygen therapy to correct hypoxemia; antifibrotic medications to slow decline; pulmonary rehabilitation for conditioning and skills; and mind–body practices to ease the lived experience of breathlessness. Clear communication among patients, pulmonologists, rehabilitation teams, and qualified traditional practitioners helps align choices with safety and personal goals, ensuring complementary methods reinforce—not replace—the benefits of oxygen therapy.